ArticleJournal of medical case reports2026
Pulmonary tuberculosis and tuberculous pleuropericarditis in a patient with pyoderma gangrenosum treated with adalimumab: a case report.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdalimumab is a tumor necrosis factor-α inhibitor, which is associated with an increased risk of tuberculosis. However, evidence regarding tuberculosis development in patients with pyoderma gangrenosum is limited, and simultaneous involvement in lungs, pleura, and pericardium is rare. This report describes a case of pulmonary tuberculosis and tuberculous pleuropericarditis associated with adalimumab administration. CASE PRESENTATION: The patient was a 59-year-old Filipino female. She began receiving adalimumab to treat pyoderma gangrenosum at the dermatology department of our hospital. The serum interferon-gamma release assay using QuantiFERON test, measured prior to administration, was negative. After five times of administration, she presented with fever, cough, and dyspnea. A chest computed tomography scan showed multiple small nodular shadows in the lung fields, right pleural effusion, and pericardial effusion. The administration of antibiotics and diuretics was ineffective. The QuantiFERON test was repeated, and was positive. The rapid sputum test for tuberculosis antigen was positive, and Mycobacterium tuberculosis was subsequently cultured 23 days later. Thus, she was diagnosed with pulmonary tuberculosis. Standard treatment with a combination of four antituberculous drugs was started, but drug susceptibility testing revealed resistance to isoniazid, so isoniazid was changed to levofloxacin. After treatment, multiple small nodular shadows in the lung fields disappeared, and the pleural and pericardial effusions completely resolved. Thus, we clinically diagnosed pulmonary tuberculosis with combined tuberculous pleuropericarditis. To the best of our knowledge, there have been no reports of pulmonary tuberculosis and tuberculous pleuropericarditis following adalimumab administration.
conclusionThis case highlights the importance of considering both pulmonary and extrapulmonary tuberculosis as potential complications of adalimumab, even in patients with initially negative interferon-gamma release assay results. Repeat testing may be crucial for early detection, especially in high-risk individuals from endemic areas.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.